Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRoflumilast
Discontinued Product
Roflumilast (Cat. No. 6641) has been withdrawn from sale for commercial reasons.
Description: Potent and selective PDE4 inhibitor
Chemical Name: 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide
Purity: ≥98% (HPLC)
Biological Activity for Roflumilast
Roflumilast is a potent and selective PDE4 inhibitor (IC50 values are 0.2 to 4.3 nM for various splice variants of PDE4). Exhibits > 1000-fold selectivity for PDE4 over other PDE family members. Demonstrates effects on functioning of neutrophils, CD4+ and CD8+ T-cells, endothelial, epithelial and smooth muscle cells, as well as fibroblasts, in vitro. Attenuates lung inflammation, mucociliary malfunction, lung fibrosis, oxidative stress, pulmonary vascular remodeling and pulmonary hypertension in animal models of COPD disease mechanisms.
Compound Libraries for Roflumilast
Roflumilast is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
Technical Data for Roflumilast
| M. Wt | 403.21 |
| Formula | C17H14Cl2F2N2O3 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 162401-32-3 |
| PubChem ID | 449193 |
| InChI Key | MNDBXUUTURYVHR-UHFFFAOYSA-N |
| Smiles | FC(F)OC(C=C1)=C(OCC2CC2)C=C1C(NC3=C(Cl)C=NC=C3Cl)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Roflumilast
References for Roflumilast
References are publications that support the biological activity of the product.
Hatzelmann et al (2010) The preclinical pharmacology of roflum. - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm.Pharmacol.Ther. 23 235 PMID: 20381629
Rabe (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br.J.Pharmacol. 163 53 PMID: 21232047
View Related Products by Target
View Related Products by Product Action
Keywords: Roflumilast, Roflumilast supplier, Roflumilast, potent, selective, phosphodiesterase, 4, PDE4, inhibitors, inhibits, PDE4A, PDE4B, PDE4C, PDE4D, Phosphodiesterases, 6641, Tocris Bioscience
2 Citations for Roflumilast
Citations are publications that use Tocris products. Selected citations for Roflumilast include:
Ronald M et al (2022) FGF1 and insulin control lipolysis by convergent pathways. Cell Metab 34 171-183.e6 PMID: 34986332
Martin J et al (2020) Optical Mapping of cAMP Signaling at the Nanometer Scale. Cell 182 1519-1530.e17 PMID: 32846156
Reviews for Roflumilast
There are currently no reviews for this product. Be the first to review Roflumilast and earn rewards!
Have you used Roflumilast?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image